Drug Interaction Report

Sunvozertinib and Mitapivat: Interaction Details

A pharmacist-reviewed analysis of the Sunvozertinib and Mitapivat interaction: the documented clinical effects, severity rating, onset, mechanism, and management considerations, with cited references throughout.

AI-assisted, pharmacist-reviewed · Source data updated Aug 8, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature

Mitapivat

Aqvesme Pyrukynd Pyrukynd®
+

Sunvozertinib

Zegfrovy
Dr. Brian Staiger, PharmD, BCPS
Medically reviewed by
Dr. Brian Staiger, PharmD, BCPS
Updated Aug 8, 2026
Editorial policy · Data sources
LinkedIn
Interaction severity
Major
Potentially serious — often needs a change or close monitoring.
How we grade severity & evidence

Severity levels

  • Contraindicated: These should generally not be used together.
  • Major: Potentially serious — often needs a change or close monitoring.
  • Moderate: Can be significant — usually manageable with monitoring.
  • Minor: Usually limited clinical impact.

Evidence grades

  • Established: Well documented — supported by controlled studies or strong clinical data.
  • Probable: Good supporting evidence, though not definitively proven.
  • Suspected: Some evidence suggests this interaction, but it is not well established.
  • Possible: Limited or conflicting evidence; the interaction may occur.
  • Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.

Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.

Of 16 documented Sunvozertinib interactions, 16 are rated major — including this one.
Worried about symptoms right now? Contact your pharmacist or prescriber, or call Poison Control at 1-800-222-1222 (US). Call 911 for an emergency.
Onset
unspecified
Evidence
theoretical
Severity
Major

What happens

Reduced sunvozertinib exposure and reduced efficacy of sunvozertinib

Interaction Deep Dive

Avoid coadministration of sunvozertinib with a strong or moderate CYP3A inducer as it may reduce sunvozertinib exposure, which may reduce the efficacy of sunvozertinib. In drug interaction studies, sunvozertinib AUC decreased by 48% and Cmax by 38% following concomitant administration of carBAMazepine (strong CYP3A inducer) 300 mg twice daily. Sunvozertinib AUC is predicted to decrease by 44% following concomitant administration of efavirenz (moderate CYP3A inducer) 600 mg once daily. If concomitant use cannot be avoided, increase the sunvozertinib dose from 200 mg to 400 mg. After discontinuing a strong or moderate CYP3A inducer, resume the sunvozertinib dose (7 to 14 days after discontinuing the strong or moderate CYP3A inducer) that was taken prior to initiating the strong or moderate CYP3A inducer1.

Why it happens (mechanism)

Induction of CYP3A-mediated metabolism of sunvozertinib

Literature reports

1 report — tap to read

a) In drug interaction studies, sunvozertinib AUC decreased by 48% and Cmax by 38% following concomitant administration of carBAMazepine (strong CYP3A inducer) 300 mg twice daily. Sunvozertinib AUC is predicted to decrease by 44% following concomitant administration of efavirenz (moderate CYP3A inducer) 600 mg once daily 1.

Common questions

Can I take Sunvozertinib and Mitapivat together?

Reduced sunvozertinib exposure and reduced efficacy of sunvozertinib Always confirm with your pharmacist or prescriber before making any change.

How serious is the Sunvozertinib and Mitapivat interaction?

It is rated major. Potentially serious — often needs a change or close monitoring.

How quickly could this interaction happen?

The documented onset is "unspecified". The timing of this interaction is not well characterized.

How strong is the evidence for this interaction?

The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.

Questions for your pharmacist

  • Does my dose of Sunvozertinib or Mitapivat need adjusting while I take them together?
  • What symptoms should prompt me to call you or my prescriber right away?
  • Does the timing of my doses matter for this combination?
  • Is there a safer alternative to one of these medications for me?

References (1)

  1. Product Information: ZEGFROVY(TM) oral tablets, sunvozertinib oral tablets. Dizal (Jiangsu) Pharmaceutical Co. Ltd (per FDA), Shanghai, China, 2025.
Was this write-up helpful?
Mitapivat

Keep reading about Mitapivat

All Mitapivat interactions (295) Mitapivat drug information
Also serious with: Mavacamten Ranolazine Ensitrelvir Zoliflodacin
Sunvozertinib

Keep reading about Sunvozertinib

All Sunvozertinib interactions (16)
Also serious with: Estradiol Transdermal Patch Cyclosporine Injection Cyclosporine Ophthalmic Nafcillin Injection
Beyond drug–drug

These medications also interact with supplements

Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:

Mitapivat + Activated Charcoal Grapefruit St. John's Wort Acacia Rigidula Adrafinil African Wild Potato Alkanna Alpine Ragwort + 146 more

major · moderate · minor — check everything you take with our drug–supplement interaction checker.

Check another combination

Our instant two-drug interaction checker is almost here.

Coming soon

The instant two-drug checker is on its way.

In the meantime, browse the directory below to look up any drug and see its documented interactions.

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist
This information is for education, not a substitute for professional medical advice. Do not start, stop, or change any medication without talking to your pharmacist or prescriber.